CCL2 and neoplasm: We have recently shown that CCL2 is predominantly expressed at the human primary tumor site of patients suffering from CaP, which leads to selective breakdown of immunological tolerance resulting in a production of anti-CCL2 autoantibodies that are likely to participate in the regulation of disease [16].